Ellodi Pharmaceuticals

📍 Blue Bell, United States🗓 Founded 2020👥 12 employees💰 Last funded Oct 2020
Pharmaceutical Manufacturing🌐 ellodipharma.com
Website LinkedIn
Ellodi Pharmaceuticals is a gastroenterology-focused specialty pharmaceutical company aiming to advance treatments for Eosinophilic Esophagitis (EoE), a rare and chronic allergic inflammatory condition. The company was established in 2020 to accelerate clinical development of EoE therapies and build on the work initiated by Adare Pharmaceuticals, particularly APT-1011, which is currently in a Phase 3 clinical trial. Despite growing awareness of EoE and its underserved patient population, no first-line FDA approved treatment exists for the disease today. Ellodi Pharmaceuticals has assembled a seasoned team with deep expertise in developing and commercializing innovative therapies for gastrointestinal disorders and rare diseases. With patients and caregivers at the center of every decision we make, we are focused on developing and delivering innovative therapies that can meaningfully improve and transform the lives of patients with EoE.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Ellodi Pharmaceuticals?
Ellodi Pharmaceuticals has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Ellodi Pharmaceuticals last raise funding?
The most recent investment in Ellodi Pharmaceuticals recorded on gritt.io was in October 2020.
When was Ellodi Pharmaceuticals founded?
Ellodi Pharmaceuticals was founded in 2020.
What industry is Ellodi Pharmaceuticals in?
Ellodi Pharmaceuticals operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Ellodi Pharmaceuticals based?
Ellodi Pharmaceuticals is headquartered in Blue Bell, United States.